For thirty years, CONRAD has been internationally renowned for its leadership in developing new, safe, and affordable contraceptive products. CONRAD continues this effort as it links preclinical and clinical research, and brings together investigators in the laboratory and the clinic. CONRAD collaborates with government agencies, nongovernmental organizations, foundations and the private sector. Through these efforts, family planning is becoming more of a choice for millions of people in developing countries.
While women currently have more contraceptive options than men, the high number of unplanned pregnancies throughout the world highlights the need for additional contraceptive options. CONRAD researchers worked closely with PATH to conduct scientific studies on a new one-size-fits-most diaphragm marketed as the Caya®, now available in Europe, Canada and the United States. Our researchers continue to investigate novel leads for new hormonal and non-hormonal contraceptives and conduct related studies in the clinic.
A13-126 – A Phase I Postcoital Testing Study of the SILCS Diaphragm Used with 3% Nonoxynol-9 Gel, ContraGel®, or no Gel
(Clinicaltrials.gov Identifier: NCT02309554)
A13-127 A PHASE I SAFETY STUDY OF THE CAYA® DIAPHRAGM USED WITH CONTRAGEL®
(Clinicaltrials.gov Identifier: NCT02462954)
A25165 – Sperm Suppression and Contraceptive Protections Provided by Norethisterone Enantate (NET-EN) Combined with Testosterone Undecanoate (TU) in Healthy Men
(ISRCTN Register: ISRCTN07760234)